Co-Diagnostics Advances Flu/RSV Test Toward FDA Clearance and Names New CSO
CODX sits 17% above its 52-week low of $1.26 on light trading volume (0.1× avg).
Summary
Co-Diagnostics submitted an FDA 510(k) for its Flu/RSV test and appointed a new CSO, while reporting a $6.3M quarterly loss and $3.6M cash balance.
Key Events · Earnings and Guidance · CODX
-
FDA 510(k) Submission
Submitted 510(k) premarket notification with concurrent CLIA Waiver by Application for Co-Dx PCR Flu A/B & RSV test on Co-Dx PCR Pro instrument.
-
New Chief Scientific Officer
Appointed Wes Lindsey, Ph.D., MBA, as CSO to lead scientific and regulatory strategy, including FDA submissions.
-
Q2 Financial Results
Net loss of $6.3 million ($1.46 per share) on revenue of $0.17 million; cash and equivalents of $3.6 million as of June 30, 2026.
-
International Clinical Progress
Initiated clinical performance studies in India for CoSara PCR MTB test; advanced Bundibugyo virus assay development.
Analysis · CODX · Industrial Applications And Services
The second quarter brought a net loss of $6.3 million and a cash position of just $3.6 million, but the more consequential development is the FDA 510(k) submission for the Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument, accompanied by a concurrent CLIA Waiver by Application. This represents a pivotal regulatory step toward commercializing the company's point-of-care molecular diagnostics platform. To steer scientific and regulatory strategy, including FDA submissions, the company appointed Wes Lindsey, Ph.D., MBA, as Chief Scientific Officer. Clinical studies for its tuberculosis test also commenced in India. With a going concern warning and critical cash burn, these regulatory and operational moves are essential for the company's survival and future revenue generation.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CODX was trading at $1.47 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $1.26 to $46.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.